Review of gemcitabine in biliary tract carcinoma.

[1]  D. D. Hoff,et al.  Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine , 2004, Investigational New Drugs.

[2]  J. Hainsworth,et al.  Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Hammel,et al.  Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Colucci,et al.  Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Bundred,et al.  Predicting sentinel node involvement: Manchester experince , 2001 .

[6]  I. Vlachonikolis,et al.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.

[7]  C. Tournigand,et al.  A phase II study of gemcitabine and oxaliplatin (gemox) in advanced biliary adenocarcinoma (ABA). Preliminary results , 2001 .

[8]  W. Scheithauer,et al.  Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[10]  T. Lehnert,et al.  Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma. , 2000, Zeitschrift fur Gastroenterologie.

[11]  F. Verderame,et al.  Biliary tract cancer: our experience with gemcitabine treatment. , 2000, Anti-cancer drugs.

[12]  M. Dintinjana,et al.  Gemcitabine in patients with nonresectable cancer of the biliary system or advanced gallbladder cancer , 2000, American Journal of Gastroenterology.

[13]  M. Dintinjana,et al.  Improvement in survival and clinical benefit response for patients with metastatic pancreatic cancer , 2000, American Journal of Gastroenterology.

[14]  W. Scheithauer,et al.  A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma , 2000, Cancer.

[15]  H. Kantarjian,et al.  Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  W. Scheithauer,et al.  Gemcitabine for the Treatment of Advanced Biliary Tract Carcinomas: Evaluation of Two Different Dose Regimens , 1999, Oncology Research and Treatment.

[17]  M. Manns,et al.  Phase II study of gemcitabine in patients with nonresectable cancer of the biliary system , 1999 .

[18]  G. Gores,et al.  Biliary tract cancers. , 1999, The New England journal of medicine.

[19]  W. Scheithauer,et al.  [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma]. , 1999, Acta medica Austriaca.

[20]  E. Raymond,et al.  Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.

[21]  J. Gallardo,et al.  Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma , 1998, Cancer.

[22]  T. Sauerbruch,et al.  Phase II Study with Gemcitabine in Gallbladder and Biliary Tract Carcinomasa , 1998, Oncology Research and Treatment.

[23]  M. Pruckmayer,et al.  The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. , 1998, European journal of cancer.

[24]  M. Castro.  Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma , 1998, Cancer.

[25]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Crinò,et al.  Combination therapy with gemcitabine in non-small cell lung cancer. , 1997, European journal of cancer.

[27]  S. Lippman,et al.  Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Larsson,et al.  Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. , 1995, Seminars in oncology.

[29]  G. Peters,et al.  Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.

[30]  G. Peters,et al.  Introduction: Gemcitabine - Status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog , 1995 .

[31]  Y Z Xu,et al.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.